Andy Serkis to Receive IBC’s Highest Award
30.7.2019 18:02:00 EEST | Business Wire | Press release
The IBC2019 International Honour for Excellence will go to Andy Serkis, the director, producer and actor who is today best known for his performance capture roles. These include Gollum, Supreme Leader Snoke, King Kong and Caesar in the Planet of the Apes series. Serkis will accept the award at the climax of the IBC2019 Awards Ceremony, on Sunday night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005738/en/
Andy Serkis (Photo: Business Wire)
“IBC is where the technology, the craft and the business of the media industry come together,” said Michael Crimp, CEO of IBC. “The International Honour for Excellence has a long history of rewarding those who have transformed our creative vision. Andy Serkis has achieved this by bringing extraordinary humanity to computer-generated characters.”
Serkis was born in England in 1964 and wanted to be an artist before becoming an actor, working in the theatre and on television. Today he is also a producer and director, with his London-based company Imaginarium Studios producing last year’s Mowgli, Legend of the Jungle, a new interpretation of Kipling’s originals adapted by Serkis, which also featured him co-starring as Baloo the bear alongside Christian Bale’s Bagheera.
His greatest achievement, though, is in making the shift from mere motion capture for CGI towards a combination of technology and the interpretive skill of the actor to create the fidelity of the performance in every detail. This is what gives the performance genuine humanity: his performance as Caesar in the three Planet of the Apes films won him an acting nomination from the Broadcast Film Critics Association.
For bringing together the highest performance standards with the latest in image recognition and CGI technology, the IBC2019 International Honour for Excellence will be presented to Andy Serkis.
“I feel incredibly honoured to have been chosen as the recipient of this year’s prestigious IBC award,” said Andy Serkis. “In turn, I must share this appreciation with the phenomenal legions of creative artists, visionaries and pioneers with whom I’ve been lucky enough to dance with on this journey of next generation storytelling.”
The IBC2019 Awards Ceremony is free to all IBC visitors. It takes place on Sunday evening 15 September at 18.30 in the RAI Auditorium, and will also see the presentation of two new awards this year, honouring achievements in social responsibility and a Young Pioneer, alongside the IBC Innovation Awards.
Earlier on Sunday Andy Serkis will feature in an IBC2019 Conference Convention Keynote , in conversation with Hollywood journalist Carolyn Giardina. They will review his career, the state of the art in motion capture, and discuss where he sees the future of technology in film and television. The Convention Keynote is at 12.30 in the Forum, and is free to attend.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005738/en/
Contact information
Aimee Moore
amoore@ibc.org
+44 (0) 20 7832 4104
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom